HEN:XETRHenkel AG & Co. KGaA Analysis
Data as of 2026-06-13 - not real-time
€510.60
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
LVMH’s price is comfortably above its short‑term moving averages yet still under the long‑term average, placing the stock in a neutral technical zone. The RSI is well above the midpoint, indicating continued buying pressure, while the MACD line sits above its signal, confirming bullish momentum. Strong gross and operating margins together with a solid return on equity underscore the company’s underlying profitability, even as revenue has slipped modestly year‑over‑year. The recent announcement of a 1,000‑1,200‑person restructuring and the divestiture of the Marc Jacobs brand signal a focused cost‑control strategy, while the approved dividend of €13 per share demonstrates a commitment to shareholder returns.
Analyst consensus remains positive with a “buy” rating and price targets suggesting upside, though a discounted cash‑flow model points to a valuation gap that warrants caution. Investors should weigh the brand’s resilience and cash‑flow generation against the modest revenue decline, elevated debt levels, and a high short‑term volatility environment.
Analyst consensus remains positive with a “buy” rating and price targets suggesting upside, though a discounted cash‑flow model points to a valuation gap that warrants caution. Investors should weigh the brand’s resilience and cash‑flow generation against the modest revenue decline, elevated debt levels, and a high short‑term volatility environment.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Neutral technical positioning near short‑term averages
- Pending impact of announced workforce reductions
- Stable dividend payout supporting income investors
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strategic divestiture improving focus on core luxury segments
- Analyst price targets indicating upside potential
- Strong cash‑flow generation to service debt and fund growth
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- World‑class brand portfolio with resilient demand
- Consistently high margins and solid ROE
- Commitment to dividend and share buy‑backs enhancing total return
Key Metrics & Analysis
Financial Health
Revenue Growth-4.70%
Profit Margin13.46%
P/E Ratio23.4
ROE16.24%
ROA7.58%
Debt/Equity53.34
P/B Ratio3.8
Op. Cash Flow€18.9B
Free Cash Flow€11.7B
Technical Analysis
TrendNeutral
RSI66.5
Support€444.35
Resistance€521.20
MA 20€477.41
MA 50€473.33
MA 200€542.52
MACDBullish
VolumeStable
Fear & Greed Index89.86
Valuation
Fair Value€266.25
Target Price€584.89
Upside/Downside14.55%
GradeFair
TypeBlend
Dividend Yield2.64%
Risk Assessment
Beta0.04
Volatility31.59%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.